Overview
- Published on October 9 in Cell Reports Medicine, the research showed that a melanoma peptide regimen kept 80% of vaccinated mice tumor-free for 250 days, while all controls developed tumors and died within 35 days.
- A tumor-lysate formulation produced 69% to 88% protection across melanoma, triple-negative breast cancer, and pancreatic ductal adenocarcinoma in challenge studies.
- Vaccinated mice resisted lung metastases after systemic exposure to cancer cells, in contrast to unvaccinated or non-nanoparticle control groups.
- The lipid nanoparticle co-encapsulates two otherwise incompatible adjuvants with antigen to coordinate multi-pathway innate signaling and strengthen antigen presentation.
- The team has launched NanoVax Therapeutics to begin translational work toward therapeutic vaccines, with outside experts emphasizing that human safety and effectiveness still require clinical testing.